Scribd Logo
Загрузить

Добро пожаловать в Scribd!

  • Project Problems

    Загружено:

    nishithathi
    20 просмотров3 страницы

    Авторское право

    © Attribution Non-Commercial (BY-NC)

    Доступные форматы

    XLSX, PDF, TXT или читайте онлайн в Scribd

    Этот документ был вам полезен?

    Это неприемлемый материал?

    Пожаловаться на этот документ

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате XLSX, PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    20 просмотров3 страницы

    Project Problems

    Загружено:

    nishithathi

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате XLSX, PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    из 3

    Modern Pharma

    Rs million
    Year 0

    Capex
    -120.0
    Sales
    Raw Material cost
    Variable cost
    Fixed cost
    Selling expense
    Overheads
    Reduction in contribution
    EBITDA
    Depreciation
    EBIT

    80.0
    24.0
    8.0
    10.0
    8.0
    4.0
    10.0
    16.0
    30.0
    -14.0

    120.0
    36.0
    12.0
    10.0
    12.0
    6.0
    10.0
    34.0
    22.5
    11.5

    160.0
    48.0
    16.0
    10.0
    16.0
    8.0
    10.0
    52.0
    16.9
    35.1

    200.0
    60.0
    20.0
    10.0
    20.0
    10.0
    10.0
    70.0
    12.7
    57.3

    160.0
    48.0
    16.0
    10.0
    16.0
    8.0
    10.0
    52.0
    9.5
    42.5

    120.0
    36.0
    12.0
    10.0
    12.0
    6.0
    10.0
    34.0
    7.1
    26.9

    80.0
    24.0
    8.0
    10.0
    8.0
    4.0
    10.0
    16.0
    5.3
    10.7

    -9.8
    30.0

    8.1
    22.5

    24.6
    16.9

    40.1
    12.7

    29.8
    9.5

    18.8
    7.1

    7.5
    5.3

    -10.0

    -10.0

    -10.0

    10.0

    10.0

    10.0

    10.2

    20.6

    31.5

    62.8

    49.2

    35.9

    20.0
    -4.0
    1.2
    22.3
    52.3

    40.0

    50.0

    40.0

    30.0

    20.0

    0.0

    120.0
    52.5
    67.5

    120.0
    69.4
    50.6

    120.0
    82.0
    38.0

    120.0
    91.5
    28.5

    Free Cash Flows


    EBIT(1-T)
    Depreciation
    Capex
    -120.0
    Working Capital
    -20.0
    Bad Debts
    Tax shield on bad debts
    Salvage value (post tax)
    Total FCF
    -140.0
    NPV

    Capex
    120.0
    Salvage value
    25.0
    Working capital
    20.0
    30.0
    Bad debts Y7
    4.0
    Raw material % of sales 0.3
    Variable cost % of sales 0.1
    Fixed cost
    10.0
    Variable seling exp % of sales
    0.1
    Overhead allocation % of 0.1
    sales
    GFA
    less acc dep
    NFA

    120.0
    30.0
    90.0

    120.0 120.0
    98.6 104.0
    21.4
    16.0

    Supreme Industries
    Rs million
    Year 0 1
    Capex
    GCA

    500.0
    320.0
    180.0
    83.3
    96.7

    500.0
    320.0
    180.0
    55.6
    124.4

    500.0
    320.0
    180.0
    37.0
    143.0

    500.0
    320.0
    180.0
    24.7
    155.3

    500.0
    320.0
    180.0
    16.5
    163.5

    500.0
    320.0
    180.0
    11.0
    169.0

    48.3
    83.3

    62.2
    55.6

    71.5
    37.0

    77.7
    24.7

    81.8
    16.5

    84.5
    11.0

    250.0
    200.0

    Sales
    Cash operating costs
    EBITDA
    Depreciation
    EBIT
    Free Cash Flows
    EBIT(1-T)
    Depreciation
    Capex
    -250.0
    Working Capital
    -150.0
    Recovery of working capital
    Salvage value (post tax)
    Total FCF
    -400.0

    131.7

    117.8

    108.5

    102.3

    98.2

    150.0
    51.0
    296.5

    250.0
    83.3
    166.7

    250.0
    138.9
    111.1

    250.0
    175.9
    74.1

    250.0
    200.6
    49.4

    250.0
    217.1
    32.9

    250.0
    228.0
    22.0

    Supreme Industries
    Rs million
    Year 0 1

    500.0
    320.0
    180.0
    55.6
    124.4
    28.5
    18.0
    77.9
    39.0
    39.0

    500.0
    320.0
    180.0
    37.0
    143.0
    22.5
    18.0
    102.5
    51.2
    51.2

    500.0
    320.0
    180.0
    24.7
    155.3
    16.5
    18.0
    120.8
    60.4
    60.4

    500.0
    320.0
    180.0
    16.5
    163.5
    10.5
    18.0
    135.0
    67.5
    67.5

    500.0
    320.0
    180.0
    11.0
    169.0
    4.5
    18.0
    146.5
    73.3
    73.3

    IRR

    23.8%

    GFA
    less acc dep
    NFA

    Capex
    GCA
    Sales
    Cash operating costs
    EBITDA
    Depreciation
    EBIT
    Interest on Term Loan
    Interest on WCapAdv
    PBT
    Tax
    PAT

    250.0
    200.0
    500.0
    320.0
    180.0
    83.3
    96.7
    30.0
    18.0
    48.7
    24.3
    24.3

    Free Cash Flows


    Equity funds
    -100.0
    PAT
    Depreciation
    Recovery of working capital
    Retirement of trade creditors
    Salvage value (post tax)
    Repayment of Term loan
    Repayment of WCapAdv
    Total FCF
    -100.0

    24.3
    83.3

    39.0
    55.6

    51.2
    37.0

    60.4
    24.7

    67.5
    16.5

    0.0
    0.0
    107.7

    -40.0
    0.0
    54.5

    -40.0
    0.0
    48.3

    -40.0
    0.0
    45.1

    73.3
    11.0
    200.0
    -50.0
    51.0
    -40.0 -40.0
    0.0 -100.0
    44.0 145.2

    GFA
    less acc dep
    NFA

    250.0
    83.3
    166.7

    250.0
    138.9
    111.1

    250.0
    175.9
    74.1

    250.0
    200.6
    49.4

    250.0
    217.1
    32.9

    250.0
    228.0
    22.0

    Term loan
    Opg bal
    Repayment
    Clg bal

    200.0
    0.0
    200.0

    200.0
    40.0
    160.0

    160.0
    40.0
    120.0

    120.0
    40.0
    80.0

    80.0
    40.0
    40.0

    40.0
    40.0
    0.0

    100.0

    100.0

    100.0

    100.0

    100.0

    100.0
    100.0

    IRR

    200.0

    Working Capital Advance


    100.0
    Repayment

    Вам также может понравиться